butabarbital decreases outcomes of sufentanil SL by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Observe Closely. Coadministration of CYP3A4 inducers may lessen sufentanil concentrations and efficacy, possibly precipitating withdrawal syndrome in individuals that have formulated Actual physical dependence to sufentanil. D